Comparison · NCT04343976-1e1e3753
Lambda Treatment vs Saline Placebo: Undetectable COVID PCR Testing at Day 14
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Lambda Treatment vs Saline Placebo: Undetectable COVID PCR Testing at Day 14. Trial comparisons, record NCT04343976-1e1e3753. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04343976-1e1e3753
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.333 | 0.0968 | 0.7 | wilson | |
| Risk in group 2 | 0.333 | 0.0968 | 0.7 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.436 | 0.436 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1 | 0.202 | 4.95 | log | |
| Odds ratio, group 1 over group 2 | 1 | 0.0907 | 11 | log | |
| Number needed to treat | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Lambda Treatment | Treatment with subcutaneous injection (180 mcg) of pegylated interferon lambda~Pegylated interferon lambda: 180 mcg subcutaneous injection of pegylated interferon lambda | 2 | 6 | OG000 |
| Group 2 | Saline Placebo | Subcutaneous injection of saline placebo~Pegylated interferon lambda: 180 mcg subcutaneous injection of pegylated interferon lambda | 2 | 6 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Undetectable COVID PCR Testing at Day 14
- Description
- Negative COVID PCR testing 14 days after first lambda dose
- Time frame
- 14 days
- Population
- All subjects providing NP swab samples at Day 14
Source ClinicalTrials.gov
Trial
- Title
- Pegylated Interferon Lambda Treatment for COVID-19
- NCT number
- NCT04343976
- Phases
- PHASE2
- Conditions
- COVID-19, COVID
- Interventions
- Pegylated interferon lambda
- Lead sponsor
- Raymond Chung
- Results first posted
- 2022-07-21
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04343976?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04343976-1e1e3753